Related Experiment Videos
Type 2 diabetes as an inflammatory cardiovascular disorder
1German Diabetes Clinic, German Diabetes Center, Leibniz Institute at the Heinrich Heine University, WHO Collaborating Center in Diabetes, European Training Center in Endocrinology and Metabolism, Düsseldorf, Germany. dan.ziegler@ddz.uni-duesseldorf.de
Current Molecular Medicine
|May 17, 2005
Summary
Type 2 diabetes significantly increases cardiovascular disease (CVD) risk. Inflammation links metabolic syndrome and atherosclerosis, suggesting lifestyle changes and anti-inflammatory treatments may reduce risks for both conditions.
Area of Science:
- Endocrinology
- Cardiology
- Immunology
Background:
- Type 2 diabetes (T2D) elevates cardiovascular disease (CVD) risk by 2-6 fold.
- Atherosclerosis and T2D share common antecedents, including insulin resistance.
- Inflammation is implicated in both atherosclerotic CVD and T2D development.
Purpose of the Study:
- To explore the role of inflammation as a link between T2D and CVD.
- To identify potential therapeutic targets for reducing CVD risk in T2D patients.
Main Methods:
- Review of existing literature on inflammation, T2D, and CVD.
- Analysis of prospective studies on inflammatory markers and disease development.
Main Results:
- Inflammatory mediators are crucial in atherosclerotic plaque development and rupture.
- Pro-inflammatory markers (e.g., CRP) and anti-inflammatory markers (e.g., adiponectin) predict T2D.
- Inflammation appears to bridge metabolic syndrome and atherosclerosis.
Conclusions:
- Inflammation is a key factor connecting T2D and CVD.
- Lifestyle modifications and anti-inflammatory agents may mitigate risks.
- Targeting inflammation offers potential for reducing the cardiovascular burden in T2D.